Published in Am J Physiol on November 01, 1990
Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation. Br J Pharmacol (1994) 1.39
Contribution of NO and cytochrome P450 to the vasodilator effect of bradykinin in the rat kidney. Br J Pharmacol (1992) 1.33
Evidence for differential roles of nitric oxide (NO) and hyperpolarization in endothelium-dependent relaxation of pig isolated coronary artery. Br J Pharmacol (1994) 1.26
Effect of nitro-L-arginine on endothelium-dependent hyperpolarizations and relaxations of pig coronary arteries. J Physiol (1992) 1.09
The role of myoendothelial cell contact in non-nitric oxide-, non-prostanoid-mediated endothelium-dependent relaxation of porcine coronary artery. Br J Pharmacol (1994) 1.08
Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol (1995) 1.03
Role of K+ channels in the vasodilator response to bradykinin in the rat heart. Br J Pharmacol (1994) 0.99
Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol (1994) 0.89
Effect of 5-hydroxytryptamine on the membrane potential of endothelial and smooth muscle cells in the pig coronary artery. Br J Pharmacol (1995) 0.86
Effects of nitric oxide synthase inhibitors, L-NG-nitroarginine and L-NG-nitroarginine methyl ester, on responses to vasodilators of the guinea-pig coronary vasculature. Br J Pharmacol (1992) 0.85
Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther (1995) 0.83
Consequences of reduced production of NO on vascular reactivity of porcine coronary arteries after angioplasty: importance of EDHF. Br J Pharmacol (2002) 0.83
Mechanism underlying substance P-induced relaxation in dog isolated superficial temporal arteries. Br J Pharmacol (1994) 0.82
Adrenergic mechanism in the control of endothelial function. Transl Med UniSa (2011) 0.77
Exogenous L-arginine does not affect angiotensin II-induced renal vasoconstriction in man. Br J Clin Pharmacol (1998) 0.75
Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem (1999) 6.59
Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 4.59
Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation (2001) 3.38
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation (1996) 3.28
Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med (2000) 3.09
Acute heart transplant rejection due to Saint John's wort. Lancet (2000) 2.71
Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 2.69
Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest (1990) 2.61
High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation (1997) 2.51
Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension (1986) 2.30
Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation (1998) 2.27
Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation (1996) 2.05
Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation (1990) 1.98
Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation (1991) 1.96
Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation (2000) 1.93
Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging with various contrast medium doses: first European multi-centre experience. Eur Heart J (2004) 1.76
Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation (1997) 1.67
Endothelial dysfunction in coronary artery disease. Annu Rev Med (1993) 1.64
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest (1998) 1.62
Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol (1998) 1.58
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest (1996) 1.50
Fibromuscular hyperplasia: extension of the disease and therapeutic outcome. Results of the University Hospital Zurich Cooperative Study on Fibromuscular Hyperplasia. Nephron (1986) 1.47
Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension (1990) 1.47
Predictors of long-term survival after valve replacement for chronic aortic regurgitation; is M-mode echocardiography sufficient? Eur Heart J (2001) 1.47
Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A (2000) 1.47
Endothelin. Key to coronary vasospasm? Circulation (1991) 1.46
Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart (2007) 1.45
Aging, serum estradiol levels, and pregnancy differentially affect vascular reactivity of the rat uterine artery. J Soc Gynecol Investig (2000) 1.44
Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol (2000) 1.43
Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation (1990) 1.42
Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension (1997) 1.41
Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler Thromb Vasc Biol (2001) 1.40
[Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions]. Schweiz Med Wochenschr (1997) 1.39
Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res (1999) 1.39
Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res (1990) 1.37
Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res (2001) 1.36
Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation (2000) 1.35
Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors. J Clin Invest (1995) 1.34
Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension (1995) 1.34
The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology? Surv Ophthalmol (1995) 1.32
Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension (1987) 1.30
Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (1998) 1.26
Compliance in hypertension: facts and concepts. J Hypertens Suppl (1985) 1.25
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23
Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation (1997) 1.22
Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation (1998) 1.20
Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci (1992) 1.19
Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation (1999) 1.18
Connective tissue growth factor. Friend or foe? Arterioscler Thromb Vasc Biol (1997) 1.17
Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension (1996) 1.16
Dark chocolate improves endothelial and platelet function. Heart (2006) 1.15
Importance of endothelium-derived nitric oxide in porcine coronary resistance arteries. Am J Physiol (1991) 1.15
Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res (1991) 1.14
Simple renal cyst and hypertension: cause or coincidence? Clin Nephrol (1986) 1.11
Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension (1997) 1.10
Endothelial regulation of vascular tone and growth. Am J Hypertens (1993) 1.09
Pulsatile stretch stimulates superoxide production and activates nuclear factor-kappa B in human coronary smooth muscle. Circ Res (1997) 1.09
Overexpression of connective tissue growth factor gene induces apoptosis in human aortic smooth muscle cells. Circulation (1999) 1.08
Local anesthetic drugs reduce endothelium-dependent relaxations of porcine ciliary arteries. Invest Ophthalmol Vis Sci (1993) 1.07
Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation (1997) 1.07
Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients. J Thromb Haemost (2009) 1.05
Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol (1990) 1.04
Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res (1992) 1.04
Academic detailing improves identification and reporting of adverse drug events. Pharm World Sci (1999) 1.03
Role of nitric oxide in the regulation of the mechanical properties of peripheral conduit arteries in humans. Hypertension (1997) 1.03
Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol (2000) 1.03
Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation (1995) 1.02
Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation (1998) 1.02
Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension (2000) 1.01
Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol (1990) 1.00
Endothelium-dependent regulation of the ophthalmic microcirculation in the perfused porcine eye: role of nitric oxide and endothelins. Invest Ophthalmol Vis Sci (1993) 1.00
Magnetic resonance-based assessment of global coronary flow and flow reserve and its relation to left ventricular functional parameters: a comparison with positron emission tomography. Circulation (2000) 1.00
Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol (2001) 1.00
Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation (1998) 0.99
HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol (2000) 0.99
Endothelium-dependent regulation of resistance arteries: alterations with aging and hypertension. J Cardiovasc Pharmacol (1992) 0.99
Heterogeneity of endothelium-dependent regulation in ophthalmic and ciliary arteries. Invest Ophthalmol Vis Sci (1993) 0.99
Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation (2001) 0.98
Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension (1992) 0.98
Coronary computed tomography angiography indicates complexity of percutaneous coronary interventions. J Invasive Cardiol (2012) 0.97
ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension (1998) 0.97
Endothelium-derived relaxing factor and protection against contractions induced by histamine and serotonin in the human internal mammary artery and in the saphenous vein. Circulation (1989) 0.96
Baroreceptor dysfunction induced by nitric oxide synthase inhibition in humans. J Am Coll Cardiol (2000) 0.96
Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and Glomerulosclerosis. J Am Soc Nephrol (2000) 0.96
Characterization of contractile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem Biophys Res Commun (1994) 0.96
Different effects of thrombin receptor activation on endothelium and smooth muscle cells of human coronary bypass vessels. Implications for venous bypass graft failure. Circulation (1997) 0.95
The vascular endothelium in hypertension. Handb Exp Pharmacol (2006) 0.95
Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor. Circulation (1993) 0.95
The endothelium in coronary artery disease. Cardiology (1997) 0.94
Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun (1997) 0.94
Endothelium-dependent regulation of vascular tone of the porcine ophthalmic artery. Invest Ophthalmol Vis Sci (1991) 0.94
Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation (1991) 0.94
Endothelium-derived relaxing and contracting factors: perspectives in nephrology. Kidney Int (1991) 0.93
Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension (2001) 0.93
Different effects of endothelin-1 on cAMP- and cGMP-mediated vascular relaxation in human arteries and veins: comparison with norepinephrine. J Cardiovasc Pharmacol (1989) 0.93